🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting more than 82 million instances annually. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Public health authorities are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This treatment, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This milestone signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Research Study Outcomes and Global Access

Based on data released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses an injection and a pill. The study involved hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Clinicians directly involved have shared optimism. Having a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.